Home

Dietrich A Stephan

CIK 1774588 · Founder and CEO · last filed 2023-08-04

Dietrich A Stephan is a Founder and CEO who has filed 9 SEC Form 4 insider transactions across 1 company since 2019. The most recent filing shows the insider exercised options covering $2.1K of NBSE on Aug 4, 2023. Across all open-market trades the lifetime net is +$60.0K, making them a net buyer over the disclosed history. 3 SEC filings were submitted jointly with Lipizzaner LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

9

Lifetime Open-Market Net

$60.0K

Filer Profile

Reported Address
213 SMITHFIELD ST
PITTSBURGH, PA 15222
Related Filers
Lipizzaner LLC — 3 joint filings, latest 2020-06-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NeuBase Therapeutics, Inc. (NBSE) Delisted Founder and CEO 137,278 $0.38 $51.9K $60.0K 9 2023-08-04

Recent Filings

9 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-08-04 NeuBase Therapeutics, Inc. (NBSE) Delisted Exer (M) +93,234 $2.1K EDGAR
2023-03-17 NeuBase Therapeutics, Inc. (NBSE) Delisted Grant (A) +153,000 $0 EDGAR
2023-02-15 NeuBase Therapeutics, Inc. (NBSE) Delisted Exer (M) +655,000 $0 EDGAR
2022-09-30 NeuBase Therapeutics, Inc. (NBSE) Delisted Exer (M) +750,000 $825 EDGAR
2022-01-25 NeuBase Therapeutics, Inc. (NBSE) Delisted Grant (A) — $0 EDGAR
2022-01-05 NeuBase Therapeutics, Inc. (NBSE) Delisted Exer (M) +42,250 $42 EDGAR
2021-04-27 NeuBase Therapeutics, Inc. (NBSE) Delisted Buy (P) +12,000 $60.0K EDGAR
2020-12-30 NeuBase Therapeutics, Inc. (NBSE) Delisted Mixed −6,369,097 $0 EDGAR
2019-07-16 NeuBase Therapeutics, Inc. (NBSE) Delisted Grant (A) +2,547,639 $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.